Protagonist Therapeutics

Protagonist Therapeutics

Founded in 2006 by Dinesh V. Patel, Protagonist Therapeutics emerged from peptide-engineering research intended to solve the oral bioavailability problem that had long confined peptide drugs to injection-only delivery. The company is headquartered in Newark, California, and has operated as a clinical-stage biopharmaceutical company since its inception, advancing its pipeline with venture backing before completing an initial public offering in 2016 on the Nasdaq Global Market under the ticker PTGX. The firm's drug-discovery engine centers on a technology platform that generates orally stable, gut-active peptides targeting validated biological pathways in immunology and hematology. Protagonist's most advanced asset, rusfertide, is a hepcidin mimetic in Phase 3 trials for polycythemia vera, a rare blood cancer, and has received Breakthrough Therapy designation from the U.S. Food and Drug Administration. A second clinical program, JNJ-2113, is an oral interleukin-23 receptor antagonist peptide developed in a global collaboration with Johnson & Johnson's Janssen Biotech, targeting moderate-to-severe plaque psoriasis and potentially other inflammatory conditions. The alliance, struck in 2017 and amended multiple times, provided milestone and royalty economics that have partially funded the firm's independent development efforts. As of its latest public filings, Protagonist employs fewer than 150 professionals and maintains a single site in California. Dinesh Patel serves as President and CEO and has guided the company through multiple financing rounds and clinical readouts. The company has no disclosed philanthropic foundation, real-asset arm, or membership in investor clubs such as Tiger 21 or YPO. In May 2024, Protagonist reported positive topline results from the Phase 3 VERIFY trial of rusfertide meeting its primary endpoint, sending shares up more than 60% in a single trading session, and later that year Johnson & Johnson expanded the IL-23 collaboration to include additional indications. Protagonist's structural differentiator is its dual-purpose platform: it functions simultaneously as an internal pipeline generator and a partnership engine for large pharmaceutical collaborators seeking oral biologics capability. Unlike many biotech firms that license a single asset from academia and build a company around it, Protagonist's discovery platform is designed to produce multiple wholly owned and partnered candidates across several therapeutic areas, creating a portfolio effect that distributes clinical risk while maintaining economics on the lead internal program.